Azitra, Inc. Announces Presentation at the 2025 BIO International Convention

Core Insights - Azitra, Inc. is a clinical stage biopharmaceutical company focused on precision dermatology, with a presentation scheduled at the BIO International Convention from June 16-19, 2025, in Boston [1][2] Company Overview - Azitra's lead program, ATR-12, targets Netherton syndrome, a rare skin disease with no approved treatments, currently in a Phase 1b clinical trial [3] - ATR-04, another program, is in development for treating moderate to severe EGFRi-associated dermal toxicity, with Fast Track designation from the FDA [3] - The company utilizes a proprietary platform of engineered proteins and a microbial library of approximately 1,500 bacterial strains, enhanced by AI and machine learning for drug discovery [3] Upcoming Events - The presentation at the BIO International Convention will be on June 17, 2025, at 12:00 PM ET, led by Dr. Travis Whitfill, showcasing the company's clinical development strategy and recent achievements [2]